Z
ZENTALIS PHARMACEUTICALS LLC
NASDAQ: ZNTL (Zentalis Pharmaceuticals, Inc.)
Kemas kini terakhir: 1 jam lalu3.11
0.03 (0.97%)
| Penutupan Terdahulu | 3.08 |
| Jumlah Dagangan | 1,259,730 |
| Harga / Jualan (P/S) | 7.13 |
| Harga / Buku (P/B) | 2.05 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -746.40% |
| EPS Cair (TTM) | -3.14 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.27% |
| Nisbah Semasa (MRQ) | 6.94 |
| Aliran Tunai Operasi (OCF TTM) | -151.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -79.27 M |
| Pulangan Atas Aset (ROA TTM) | -26.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Zentalis Pharmaceuticals, Inc. | Bercampur | Menurun |
AISkor Stockmoo
-2.0
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -2.00 |
|
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.58% |
| % Dimiliki oleh Institusi | 80.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| 5Am Venture Management, Llc | 30 Jun 2026 | 3,947,913 |
| Squadron Capital Management Llc | 30 Jun 2026 | 3,700,000 |
| Acadian Asset Management Llc | 30 Jun 2026 | 2,681,900 |
| Two Sigma Advisers, Lp | 31 Dec 2025 | 1,483,500 |
| Opaleye Management Inc. | 30 Jun 2026 | 1,412,656 |
| Orbimed Advisors Llc | 30 Jun 2026 | 1,390,576 |
| Decheng Capital Llc | 30 Jun 2026 | 1,323,327 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |